Monitoring high-risk bladder cancer

Current Opinion in Urology

Volumn 22, Issue 5, 2012, Pages 421-426

  Schwentner, Christian ^a   Stenzl, Arnulf ^a   Gakis, Georgios ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; INTERLEUKIN 2; NUCLEAR MATRIX PROTEIN 22;

BCG VACCINATION; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CARCINOMA IN SITU; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CYSTOSCOPY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INTRAVENOUS PYELOGRAPHY; LOW RISK POPULATION; NOMOGRAM; PRIORITY JOURNAL; RADICAL RESECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOSIS; TRANSURETHRAL RESECTION;

BCG VACCINE; DISEASE PROGRESSION; HUMANS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864856639     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283555d04     Document Type: Review

References (28)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:465-466; discussion 475-467.
2. Sternberg CN, de Mulder P, Schornagel JH, et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50-54. (Pubitemid 41814532)
3. Hernandez V, De La Pena E, Martin MD, et al. External validation and applicability of the EORTC risk tables for nonmuscle-invasive bladder cancer. World J Urol 2011; 29:409-414.
4. Mian C, Lodde M, Comploj E, et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006; 59:984-987. (Pubitemid 44422855)
5. Babjuk M, Oosterlinck W, Sylvester R, et al. European Association of Urology (EAU). EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303-314.
6. Mian C, Maier K, Comploj E, et al. uCyt/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006; 108:60-65. (Pubitemid 43291246)
7. Galvan AB, Salido M, Espinet B, et al. A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of nonmuscle-invasive urothelial cell carcinoma: a prospective study. Cancer Cytopathol 2011; 119:395-403.
8. Schwentner C, Hennenlotter J, Kuehs U, et al. Second-line application of urine-based molecular markers in transitional cell carcinoma diagnostics: a contribution to cost effectiveness. Eur Urol Suppl 2011; 10:72.
9. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009; 124:2899-2904.
10. Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol 2012 [Epub ahead of print]. doi: 10.1093/annonc/mdr619.
11. Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012; 61:810-817.
12. Gradilone A, Petracca A, Nicolazzo C, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 2010; 106:710-715.
13. Giannarini G, Kessler TM, Thoeny HC, et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol 2010; 58:486-494.
14. International Bladder Cancer Nomogram Consortium BB, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24:3967-3972. (Pubitemid 46630745)
15. Karakiewicz PI, Shariat S, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176:1354-1361.
16. Zaak D, Burger M, Otto W, et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 2010; 106:342-348.
17. Soloway M, Khoury S. Bladder tumors. International Consultation on Urological Disease; Paris; 2012.
18. Gakis G, Schwentner C, Todenhoefer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012. doi: 10.1111/j.1464-410X.2011.10839.x.
19. Gilbert L, Basso O, Sampalis J, et al. for the DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012; 13:285-291.
20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545. (Pubitemid 32173595)
21. Pepys MB. C-reactive protein fifty years on Lancet 1998; 1:653-657.
22. Gakis G, Todenhöfer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011; 108:1800-1805.
23. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011; 8:659-666.
24. Caine GJ, Lip GY, Blann AD, Platelet-derived VEGF. Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004; 36:273-277. (Pubitemid 38789281)
25. Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancerrelated thrombocytosis. Am J Clin Oncol 2003; 26:135-140. (Pubitemid 36443554)
26. Todenhöfer T, Renninger M, Schwentner C, et al. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathologic risk factors. BJU Int 2012 [Epub ahead of print].
27. Gakis G, Todenhöfer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol 2011; 21:428-433.
28. Kruck S, Gakis G, Stenzl A. Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors. Anticancer Res 2011; 31:2053-2057.